/

SYRS

Syros Pharmaceuticals, Inc.Closed

0.0004000.00 0.00%USD

OTC Markets OTCPK · as of Oct 12, 16:00 ET · 15m delay

Open

0.000500

Prev close

0.000400

Day range

0.0005000.000500

52-week range

0.0001000.0200

Volume

9040.07×

Mkt cap

10.73K

P/E ttm

—

Fwd P/E

-0.00

EPS ttm

-6.14

Div yield

0.00%

Earnings

—

From 52w high

−98.00%

Price Chart

Yahoo Finance · delayed

SYRSOct 12, 2026O 0.0004H 0.0004L 0.0004C 0.00040.0000 (0.00%)Vol 17.01K

SMA 500.0005
SMA 2000.0003

1Y change −92.00% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SYRS Syros Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: 0.00%
1 month: 0.00%
3 months: +300.00%
6 months: +14.29%
Year to date: +14.29%
1 year: −92.00%

Valuation & ownership

Market cap: 10.73K
Enterprise value: 1.96M
P/E (ttm): —
Forward P/E: -0.00
PEG ratio: —
Price / book: —
Price / sales (ttm): 0.03
EV / EBITDA: -0.02
EPS (ttm): -6.14
EPS (forward): -2.61
Beta (5y monthly): 1.69
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 26.83M
Float: 26.83M
Short % of float: 17.01%
Short ratio (days): 0.09
Held by insiders: 0.00%
Held by institutions: 0.00%
Avg volume (3m): 12.49K
50-day average: 0.000544
200-day average: 0.000333
52-week change: −92.00%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 48.4
vs 50-day SMA: −26.47%
vs 200-day SMA: +18.34%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 121.63%
Realised vol (20d, ann.): 1751.7%
From 52-week high: −98.00%
From 52-week low: +300.00%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

8.75

+2,187,400.00% implied

Low 4.00Median 5.50High 20.00

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 386.00K

DES

About Syros Pharmaceuticals, Inc.

Yahoo Finance profile

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 68
Headquarters: Cambridge, MA, United States
Website: syros.com
Officers: Dr. James E. Bradner M.D. Founder
Dr. Nathanael S. Gray Ph.D. Scientific Founder & Member of Scientific Advisory Board
Matthew Foster Chief Restructuring Officer

SEAS

Seasonality · SYRS

2016–2026 · monthly returns

Strongest month Oct +14.60%Weakest month Sep −16.31%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	128.6	-75.0	0.0	0.0	0.0	-50.0	0.0	300.0	0.0	0.0			+14.3%
2025	-23.8	-18.3	-79.9	5.6	-1.3	-26.0	-94.6	66.7	-95.0	300.0	25.0	-30.0	−99.8%
2024	-8.3	1.7	-26.3	0.9	-5.6	1.2	16.3	-72.7	31.1	17.2	-89.2	-15.4	−97.1%
2023	42.3	-26.4	-29.0	19.1	21.1	-18.2	26.3	-2.0	1.3	-37.0	10.4	183.3	+117.0%
2022	-39.3	-34.8	-7.8	-29.3	-2.4	17.2	-18.5	2.0	-19.6	-22.0	-21.1	-9.3	−89.0%
2021	0.9	-23.3	-11.0	-19.3	6.8	-15.5	-15.2	14.7	-15.7	-7.6	-4.1	-17.7	−70.0%
2020	2.2	-17.1	1.4	42.2	16.1	8.9	-11.0	39.6	-33.3	-24.5	22.2	33.1	+57.0%
2019	7.5	13.4	34.6	-20.9	-18.4	56.9	-19.2	46.7	-5.4	-50.1	-1.4	35.5	+24.1%
2018	-1.5	10.0	23.1	-6.0	1.9	-17.9	-0.9	21.4	-3.1	-44.8	3.5	-18.2	−42.8%
2017	-10.8	1.8	44.2	-4.6	5.3	0.6	41.8	-14.2	-24.8	16.8	-13.7	-34.5	−20.0%
2016							-36.2	18.3	1.2	-2.0	-0.1	-10.5	−33.0%

SYRS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SYRS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Syros Pharmaceuticals, Inc.

Seasonality · SYRS

Insider Activity · SYRS

Congress Trades · SYRS

Investors Holding SYRS

Investors Holding SYRS

Congress Trades · SYRS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Syros Pharmaceuticals, Inc.

Earnings & Dividends

News

Insider Activity · SYRS

Seasonality · SYRS